<DOC>
	<DOCNO>NCT02744287</DOCNO>
	<brief_summary>In protocol , patient non-resectable pancreatic cancer autologous T cell collect via apheresis genetically modify use retrovirus express anti-PSCA Chimeric Antigen Receptor ( CAR ) . The T cell reinfused accord dose-finding schedule subject identify adequate lymphopenia provide homeostatic expansion adoptively transfer , engineer T cell therapeutic product .</brief_summary>
	<brief_title>Prostate Stem Cell Antigen ( PSCA ) -Specific CAR T Cells In Subjects With Non-Resectable Pancreatic Cancer</brief_title>
	<detailed_description>This Phase I , single center , open-label , non-randomized , feasibility , safety dose-finding study . The purpose clinical trial determine safety administration anti-PSCA CAR T cell ( BPX-601 ) subject non-resectable pancreatic adenocarcinoma , follow evaluation safety rimiducid infusion BPX-601 administration , persistence CAR-T cell time single rimiducid infusion .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Histologically confirm adenocarcinoma pancreas nonresectable disease . Subjects mixed histology may include predominant component adenocarcinoma . Tumor positive PSCA expression . Failed standard therapy ( chemotherapy surgery ) investigational therapy non resectable disease , document refusal standard treatment . Tumor must evaluable CT scan ( MRI , subject allergic CT contrast medium ) . Age ≥ 18 year . If female subject childbearing potential , must negative serum pregnancy test document prior administration BPX601 . If sexually active , subject must agree use contraception consider adequate appropriate Investigator 3 month administration BPX601 . Life expectancy &gt; 12 week . Signed informed consent . Performance status : Karnofsky score &gt; 60 % . Subjects must adequate venous access apheresis agree use central line apheresis collection . Subject adequate organ function measure : 1 . Cardiac : leave ventricular ejection fraction rest must ≥ low limit institutional normal . 2 . Hematologic : ) White Blood Cell ( WBC ) ≥ 2,000/μl , ii ) Absolute Neutrophil Count ( ANC ) ≥ 1,000/μl , iii ) Platelets ≥ 50 x 10^3/μl , iv ) Hemoglobin ≥ 9 g/dL . 3 . Hepatic : direct bilirubin ≤ 1.5 x upper limit normal , aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) ≤ 2.5 x upper limit normal . 4 . Renal : creatinine ≤ 1.5 x upper limit normal . 5 . Pulmonary : forced expiratory volume ( FEV ) 1 , force vital capacity ( FVC ) , diffuse capacity lung carbon monoxide ( DLCO ) ≥ 50 % predict ( correct hemoglobin ) . Subjects islet cell neoplasms . Participation investigational drug study &lt; 28 day prior BPX601 infusion . Chemotherapy immunotherapy &lt; 2 week prior BPX601 , salvage/lymphodepletion chemotherapy . Active autoimmune disease require immunosuppressive therapy &lt; 4 week prior screen . Treatment systemic high dose prednisone ≥ 0.5mg/kg/day equivalent within 7 halflives prescribe corticosteroid prior date leukapheresis BPX601 infusion . Uncontrolled bacterial , viral fungal infection , medical condition determine Investigator risk enrol protocol . Known HIV , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) positivity subject meeting selection criterion define Foundation Accreditation Cell Therapy ( FACT ) American Association Blood Banks ( AABB ) . Positive serum urine β human chorionic gonadotropin ( HCG ) test breastfeeding . Fertile men woman unwilling use effective form birth control abstinence 3 month BPX601 administration . Bovine product allergy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Non Resectable Pancreatic Cancer</keyword>
	<keyword>BPX-601</keyword>
	<keyword>AP1903</keyword>
	<keyword>CAR T</keyword>
	<keyword>PSCA-CAR</keyword>
</DOC>